Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

780 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA.
Smith J, Nazare JA, Borel AL, Aschner P, Barter PJ, Van Gaal L, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP. Smith J, et al. Among authors: despres jp. Diabetes Obes Metab. 2013 Jul;15(7):629-41. doi: 10.1111/dom.12075. Epub 2013 Feb 24. Diabetes Obes Metab. 2013. PMID: 23356633
Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial.
Punthakee Z, Alméras N, Després JP, Dagenais GR, Anand SS, Hunt DL, Sharma AM, Jung H, Yusuf S, Gerstein HC. Punthakee Z, et al. Among authors: despres jp. Diabet Med. 2014 Sep;31(9):1086-92. doi: 10.1111/dme.12512. Epub 2014 Jun 19. Diabet Med. 2014. PMID: 24890138 Clinical Trial.
Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity.
Taskinen MR, Söderlund S, Bogl LH, Hakkarainen A, Matikainen N, Pietiläinen KH, Räsänen S, Lundbom N, Björnson E, Eliasson B, Mancina RM, Romeo S, Alméras N, Pepa GD, Vetrani C, Prinster A, Annuzzi G, Rivellese A, Després JP, Borén J. Taskinen MR, et al. Among authors: despres jp. J Intern Med. 2017 Aug;282(2):187-201. doi: 10.1111/joim.12632. Epub 2017 Jun 27. J Intern Med. 2017. PMID: 28548281 Free article.
A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care.
Teoh H, Després JP, Dufour R, Fitchett DH, Goldin L, Goodman SG, Harris SB, Langer A, Lau DC, Lonn EM, Mancini GB, McFarlane PA, Poirier P, Rabasa-Lhoret R, Tan MK, Leiter LA. Teoh H, et al. Among authors: despres jp. Diabetes Obes Metab. 2013 Dec;15(12):1093-100. doi: 10.1111/dom.12134. Epub 2013 Jun 11. Diabetes Obes Metab. 2013. PMID: 23683111
Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese men.
Matikainen N, Söderlund S, Björnson E, Bogl LH, Pietiläinen KH, Hakkarainen A, Lundbom N, Eliasson B, Räsänen SM, Rivellese A, Patti L, Prinster A, Riccardi G, Després JP, Alméras N, Holst JJ, Deacon CF, Borén J, Taskinen MR. Matikainen N, et al. Among authors: despres jp. Nutr Metab Cardiovasc Dis. 2017 Jun;27(6):534-542. doi: 10.1016/j.numecd.2017.03.003. Epub 2017 Mar 18. Nutr Metab Cardiovasc Dis. 2017. PMID: 28428027 Clinical Trial.
Reduction of visceral adipose tissue during weight loss.
Doucet E, St-Pierre S, Alméras N, Imbeault P, Mauriège P, Pascot A, Després JP, Tremblay A. Doucet E, et al. Among authors: despres jp. Eur J Clin Nutr. 2002 Apr;56(4):297-304. doi: 10.1038/sj.ejcn.1601334. Eur J Clin Nutr. 2002. PMID: 11965505 Clinical Trial.
780 results